Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JW0201 Add-on Therapy in Type 2 Diabetes
NCT05814406Phase 3Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Jan 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of anagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by JW Pharmaceutical Corporation. Primary endpoint: Change in Hemoglobin A1c at 24 weeks. Started Jan 2023; status: completed.
02
Drugs
anagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05814406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05814406.